Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Entera Bio Ltd.NASDAQ: ENTX
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities rises 10.2% from a year ago
Other non-current liabilities stood at $603K at the end of Q1 FY2026, up 10.2% from a year earlier and up 40.6% from the prior quarter. Over 3 fiscal years it compounded at +137.6% a year.
Context
- Other non-current liabilities amounted to 4.6% of total assets at the end of Q1 FY2026, up 2.1 pp from a year earlier.
- Other non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +10.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 429K USD
- Year-over-year change
- +1240.6%
- 4-year CAGR
- +32.8%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 429K | +1240.6% |
| FY2024 | 2024-12-31 | 32K | +0.0% |
| FY2023 | 2023-12-31 | 32K | +0.0% |
| FY2022 | 2022-12-31 | 32K | -76.8% |
| FY2021 | 2021-12-31 | 138K | — |
Other Non-current Liabilities vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 other non-current liabilities of $603K is the 3rd highest of the 10 companies compared; the peer median is $26K.
- Its year-over-year change of +10.2% is the 3rd highest of 6, against a peer median of -16.1%.
- Other non-current liabilities amounts to 4.6% of total assets for ENTX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | Mar 2026 | $77.35M | +310.5% | — | 115.8% |
| Mar 2026 | $2.14M | +13.0% | +12.9% | 1.8% | |
| Mar 2026 | $603K | +10.2% | +137.6% | 4.6% | |
| Mar 2026 | $247K | -99.9% | -89.4% | 0.1% | |
| Mar 2026 | $91K | — | -1.8% | 0.2% | |
| Mar 2026 | $26K | -16.1% | -70.8% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Apr 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | -$1 | — | — | 0.0% | |
| Peer median (excluding ENTX) | $26K | -16.1% | -36.3% | 0.0% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.